Lung Cancer

NON SMALL CELL 

 Stage IB, II, IIIA

  • Alliance A081105Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
  • Alliance A151216– Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  • ECOG E4512– Randomized Phase III Double-Blind Trial for Surgical Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
  • ECOG EA5142– A Phase III Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
  • SWOG S1507– A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer and Progressive Disease Following one or two Prior Systemic Therapies (Temporarily Closed)

STAGE III

  • RTOG 1306– A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III NSCLC

STAGE IIIB/IV

  • SWOG S1400A Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Stage IIIB/IV  Lung Cancer

SMALL CELL LUNG

  • CALGB 30610– Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited SCLC also Receiving Cisplatin and Etoposide
  • NRG-CC003– A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Metastatic Lung Cancer

  •  RTOG 0631– A Randomized Phase II/III Study of Image Guided Radiosurgery/SBRT for Localized Spine Metastasis
  • SWOG 1403– A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer
  • NRG-LU002– A Randomized Phase II/III Trial of Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC)